1194235-41-0 Usage
Description
Bortezomib Impurity 9, also known as N-(2-Pyrazinylcarbonyl)-L-phenylalanyl-N-[(1R)-1-borono-3-methylbutyl]-L-phenylalaninamide, is an impurity of Bortezomib (B675700). Bortezomib is a tripeptide boronic acid proteasome inhibitor that functions as an antitumor agent. This impurity is a byproduct formed during the synthesis process of Bortezomib and may have potential applications in various fields due to its chemical properties.
Uses
Used in Pharmaceutical Industry:
Bortezomib Impurity 9 is used as a research compound for understanding the synthesis process, quality control, and potential applications of Bortezomib. It aids in the development of improved manufacturing techniques and the identification of novel therapeutic agents.
Used in Cancer Research:
Bortezomib Impurity 9 serves as a valuable tool in cancer research, enabling scientists to study the mechanisms of action and potential synergistic effects with other antitumor agents. This can lead to the discovery of new treatment strategies and the enhancement of existing therapies.
Used in Drug Development:
As a related compound to Bortezomib, Bortezomib Impurity 9 may have potential applications in drug development. It can be used to investigate the structure-activity relationship of proteasome inhibitors and contribute to the design of more effective and targeted cancer treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 1194235-41-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,9,4,2,3 and 5 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1194235-41:
(9*1)+(8*1)+(7*9)+(6*4)+(5*2)+(4*3)+(3*5)+(2*4)+(1*1)=150
150 % 10 = 0
So 1194235-41-0 is a valid CAS Registry Number.
1194235-41-0Relevant articles and documents
TRIPEPTIDE BORONIC ACID OR BORONIC ESTER, PREPARATIVE METHOD AND USE THEREOF
-
, (2016/11/07)
The present invention discloses proteasome inhibitors of tripeptide boronic acids or boronic esters represented by Formula (I), preparative method and use thereof. The proteasome inhibitors are therapeutical agents for treating malignant tumor, various nervous system degenerative diseases, muscle cachexia or diabetes, wherein the malignant tumor is leukemia, gastric cancer, hepatocarcinoma or nasopharyngeal carcinoma.
